{"id":"W4386002608","doi":"10.1016/j.blre.2023.101128","title":"Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","year":2023,"lang":"en","type":"review","venue":"Blood Reviews","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Takeda Oncology; Genentech; National Institutes of Health; Foundation Medicine; Sierra Oncology; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Daiichi-Sankyo; MacroGenics; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Argenx; Pfizer; Incyte; CTI Biopharma; bluebird bio; Agios Pharmaceuticals; Syndax Pharmaceuticals; National Heart, Lung, and Blood Institute; Edward P. Evans Foundation; Acceleron; Loxo Oncology; Astex Pharmaceuticals; Leukemia and Lymphoma Society; Daiichi Sankyo Europe; Servier; Gilead Sciences; Jazz Pharmaceuticals; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Myelodysplastic syndromes; Medicine; Risk stratification; Risk assessment; International Prognostic Scoring System; Intensive care medicine; Internal medicine; Computer science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003465644,0.0007153159,0.003115271,0.002284986,0.000190778,0.001775647,0.001430422,0.00105145,0.001618003],"category_scores_gemma":[0.004925188,0.0002919225,0.001732942,0.002262714,0.0004318752,0.0009492628,0.0006152349,0.001726402,0.0005475017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009298123,"about_ca_system_score_gemma":0.002126908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002427824,"about_ca_topic_score_gemma":0.004438548,"domain_scores_codex":[0.9991249,0.0002544199,0.0001984177,0.0001378384,0.00023658,0.00004781748],"domain_scores_gemma":[0.9978186,0.001384564,0.0003633884,0.0000381511,0.0003409371,0.00005444439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001877934,0.00003950132,0.0005520506,0.02319863,0.0005854366,0.00002746435,0.00002989535,0.0003375411,0.0002148968,0.0008847909,0.01658607,0.9573558],"study_design_scores_gemma":[0.0007308481,0.0007159901,0.01281968,0.07981488,0.009514192,0.001461925,0.0001958837,0.001193669,0.0007354851,0.005534152,0.8871439,0.0001394329],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007872949,0.9994162,0.00006263192,0.0002230689,0.00007547075,0.000005368661,0.00002694148,0.000002871687,0.0001088103],"genre_scores_gemma":[0.001003032,0.9980366,0.0003562151,0.0002881515,0.0001494352,0.00001031812,0.00007529178,0.000001513936,0.00007941498],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003465644,"threshold_uncertainty_score":0.01832825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1103538405615796,"score_gpt":0.4120282487860294,"score_spread":0.3016744082244499,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}